“Increasing Demand Driven by Surgical Volume and Patient-Centric Care”
- A significant and accelerating trend in the global postoperative nausea and vomiting treatment market is the rising volume of surgeries, including minimally invasive and outpatient procedures, which has led to a larger at-risk population requiring effective antiemetic therapy
- For instance, in 2024, healthcare providers across North America and Europe reported a substantial increase in ambulatory surgeries, prompting higher adoption of fast-acting and short-duration anti-nausea medications to enable quicker recovery and discharge
- In addition, the shift towards enhanced recovery after surgery (ERAS) protocols is fueling the need for targeted antiemetic treatment options that reduce hospital stays and improve patient comfort. Drugs such as ondansetron, dexamethasone, and aprepitant continue to be integral components of multi-modal PONV management strategies
- The emphasis on patient-centric care is also driving demand for medications with fewer side effects and higher tolerability. This is encouraging pharmaceutical innovation focused on novel formulations such as long-acting injectables, transdermal patches, and oral dissolving tablets
- The increasing burden of chemotherapy-induced nausea and vomiting (CINV), along with PONV, is broadening the market scope, offering pharmaceutical companies opportunities to develop dual-indication therapies
- Furthermore, rising awareness of preventive treatment protocols, especially in high-risk patient populations (e.g., females, non-smokers, patients with prior history of motion sickness or nausea), is driving the prophylactic use of PONV treatments across hospitals and outpatient surgical centers worldwide
